Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Filing tables
Filing exhibits
- 8-K Current report
- 3.1 EX-3.1
- 3.2 EX-3.2
- 10.1 EX-10.1
- 10.2 EX-10.2
- 10.3 EX-10.3
- 10.4 EX-10.4
- 10.6 EX-10.6
- 10.7 EX-10.7
- 10.8 EX-10.8
- 10.9 EX-10.9
- 10.10 EX-10.10
- 10.11 EX-10.11
- 10.12 EX-10.12
- 10.13 EX-10.13
- 14.1 EX-14.1
- 16.1 EX-16.1
- 23.1 EX-23.1
- 99.1 EX-99.1
- 99.2 EX-99.2
- 99.3 EX-99.3
- 99.4 EX-99.4
- 99.5 EX-99.5
- 99.6 EX-99.6
- 99.7 EX-99.7
- Download Excel data file
- View Excel data file
KRRO similar filings
- 9 Jan 24 Other Events
- 29 Nov 23 Departure of Directors or Certain Officers
- 14 Nov 23 Departure of Directors or Certain Officers
- 6 Nov 23 Entry into a Material Definitive Agreement
- 27 Sep 23 Termination of a Material Definitive Agreement
- 15 Aug 23 Termination of a Material Definitive Agreement
- 10 Aug 23 Frequency Therapeutics Provides Business Updates and Second Quarter 2023 Financial Results
Filing view
External links
Exhibit 16.1
November 6, 2023
Securities and Exchange Commission
Washington, D.C. 20549
Commissioners:
We have read Korro Bio Inc.’s (formerly known as Frequency Therapeutics, Inc.) statements included under Item 4.01 of its Form 8-K filed on November 6, 2023 and we agree with such statements concerning our firm.
/s/ RSM US LLP